Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma

被引:30
|
作者
Gu, Jintao [1 ]
Mu, Nan [2 ]
Jia, Bo [3 ]
Guo, Qingdong [3 ]
Pan, Luxiang [1 ]
Zhu, Maorong [1 ]
Zhang, Wangqian [1 ]
Zhang, Kuo [1 ]
Li, Weina [1 ]
Li, Meng [1 ]
Wei, Lichun [4 ]
Xue, Xiaochang [5 ]
Zhang, Yingqi [1 ]
Zhang, Wei [1 ]
机构
[1] Fourth Mil Med Univ, Biotechnol Ctr, Sch Pharm, State Key Lab Canc Biol, Xian, Peoples R China
[2] Fourth Mil Med Univ, Sch Basic Med, Dept Physiol & Pathophysiol, Xian, Peoples R China
[3] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian, Peoples R China
[4] Fourth Mil Med Univ, Xijing Hosp, Dept Radiotherapy, Xian, Peoples R China
[5] Shaanxi Normal Univ, Coll Life Sci, Xian, Peoples R China
基金
中国国家自然科学基金;
关键词
DNA damage repair; glioblastoma; glioma stem cell; radioresistance; STEM-CELLS; RADIOSENSITIZATION; PATHWAYS; COMPLEX; CANCER;
D O I
10.1093/neuonc/noab288
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Compelling evidence suggests that glioblastoma (GBM) recurrence results from the expansion of a subset of tumor cells with robust intrinsic or therapy-induced radioresistance. However, the mechanisms underlying GBM radioresistance and recurrence remain elusive. To overcome obstacles in radioresistance research, we present a novel preclinical model ideally suited for radiobiological studies. Methods With this model, we performed a screen and identified a radiation-tolerant persister (RTP) subpopulation. RNA sequencing was performed on RTP and parental cells to obtain mRNA and miRNA expression profiles. The regulatory mechanisms among NF-kappa B, YY1, miR-103a, XRCC3, and FGF2 were investigated by transcription factor activation profiling array analysis, chromatin immunoprecipitation, western blot analysis, luciferase reporter assays, and the MirTrap system. Transferrin-functionalized nanoparticles (Tf-NPs) were employed to improve blood-brain barrier permeability and RTP targeting. Results RTP cells drive radioresistance by preferentially activating DNA damage repair and promoting stemness. Mechanistic investigations showed that continual radiation activates the NF-kappa B signaling cascade and promotes nuclear translocation of p65, leading to enhanced expression of YY1, the transcription factor that directly suppresses miR-103a transcription. Restoring miR-103a expression under these conditions suppressed the FGF2-XRCC3 axis and decreased the radioresistance capability. Moreover, Tf-NPs improved radiosensitivity and provided a significant survival benefit. Conclusions We suggest that the NF-kappa B-YY1-miR-103a regulatory axis is indispensable for the function of RTP cells in driving radioresistance and recurrence. Thus, our results identified a novel strategy for improving survival in patients with recurrent/refractory GBM.
引用
收藏
页码:1056 / 1070
页数:15
相关论文
共 50 条
  • [21] Targeting IL-6/STAT3 signaling in EGFR-mutant drug tolerant persister cells
    Patel, Sonia A.
    Nilsson, Monique
    Yang, Yan
    Shen, Li
    Wang, Jing
    Poteete, Alissa
    Yu, Xiaoxing
    Ren, Xiaoyang
    Le, Xiuning
    Heymach, John
    CANCER RESEARCH, 2023, 83 (07)
  • [22] Targeting HSP90 with the novel inhibitor NW457 attenuates radioresistance of human glioblastoma cells
    Kinzel, L.
    Seidl, K.
    Winssinger, N.
    Friedl, A. A.
    Belka, C.
    Lauber, K.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S170 - S171
  • [23] miR-135b Contributes to the Radioresistance by Targeting GSK3β in Human Glioblastoma Multiforme Cells
    Xiao, Songhua
    Yang, Zhen
    Lv, Ruiyan
    Zhao, Jia
    Wu, Ming
    Liao, Yiwei
    Liu, Qing
    PLOS ONE, 2014, 9 (09):
  • [24] Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer
    Izumi, Motohiro
    Costa, Daniel B.
    Kobayashi, Susumu S.
    LUNG CANCER, 2024, 194
  • [25] TARGETING GLIOBLASTOMA STEM CELLS BY PERTURBING A NOVEL GENE REGULATORY CLUSTER TO REDUCE TUMOR RECURRENCE
    Deng, Changwang
    Sebastian, Mathew
    Le, Son
    Chen, Dongjiang
    Thomas, Nagheme
    Tran, David
    NEURO-ONCOLOGY, 2017, 19 : 232 - 232
  • [26] Targeting drug-tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells
    Song, Xiaohai
    Lan, Yang
    Zheng, Xiuli
    Zhu, Qianyu
    Liao, Xuliang
    Liu, Kai
    Zhang, Weihan
    Peng, Qiangbo
    Zhu, Yunfeng
    Zhao, Linyong
    Chen, Xiaolong
    Shu, Yang
    Yang, Kun
    Hu, Jiankun
    MEDCOMM, 2023, 4 (05):
  • [27] Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma
    Zhang, Peng
    Miska, Jason
    Lee-Chang, Catalina
    Rashidi, Aida
    Panek, Wojciech K.
    An, Shejuan
    Zannikou, Markella
    Lopez-Rosas, Aurora
    Han, Yu
    Xiao, Ting
    Pituch, Katarzyna C.
    Kanojia, Deepak
    Balyasnikova, Irina V.
    Lesniak, Maciej S.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (47) : 23714 - 23723
  • [28] MiR-10b decreases sensitivity of glioblastoma cells to radiation by targeting AKT
    Zhen, Limin
    Li, Jian
    Zhang, Mingran
    Yang, Kun
    JOURNAL OF BIOLOGICAL RESEARCH-THESSALONIKI, 2016, 23 : 1 - 10
  • [29] Targeting EphA3 on Glioblastoma Stem Cells with CART Cell Therapy to Overcome GBM Recurrence
    Ogbodo, Ekene J.
    Sakemura, Reona L.
    Siegler, Elizabeth L.
    Manriquez-Roman, Claudia
    Truc Huynh
    Girsch, James H.
    Feigin, Jennifer M.
    Sirpilla, Olivia L.
    Yun, Kun
    Stewart, Carli M.
    Xia, Hong
    Ruiz, Omar Gutierrez
    Fonkoua, Lionel Kankeu
    Hefazi, Mehrdad
    Ruff, Michael W.
    Kenderian, Saad S.
    MOLECULAR THERAPY, 2024, 32 (04) : 123 - 123
  • [30] Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer
    Fujimura, Takaaki
    Furugaki, Koh
    Mizuta, Hayato
    Muraoka, Satoshi
    Nishio, Makoto
    Adachi, Jun
    Uchibori, Ken
    Miyauchi, Eisaku
    Hayashi, Hidetoshi
    Katayama, Ryohei
    Yoshiura, Shigeki
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)